Research programme: cancer radiotherapeutics - Algeta

Drug Profile

Research programme: cancer radiotherapeutics - Algeta

Alternative Names: 227Th conjugates; FGFR2-targeted thorium-227 conjugate; HER2-targeted thorium-227 conjugate; PSMA targeted thorium-227 conjugate; Targeted thorium conjugates - Algeta; TH-1 programme; thorium-227 conjugates; TTC - Algeta

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algeta
  • Developer Algeta; Norwegian Radium Hospital
  • Class Antibodies; Drug conjugates; Monoclonal antibodies; Peptides; Proteins; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2017 Pharmacodynamic results from a preclinical trial in Cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 22 Mar 2017 Preclinical development is ongoing in Norway
  • 17 Apr 2014 Lumiphore receives phase II SBIR grant from the US National Science Foundation for the development of cancer radiotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top